{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:04:29Z","timestamp":1789981469313,"version":"4.0.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"DOI":"10.1007\/s41669-026-00676-5","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T08:33:17Z","timestamp":1789979597000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Health Outcomes, Healthcare Resource Use, and Economic Burden of Invasive Meningococcal Disease in the United States Among Children Aged <11 Years"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8193-999X","authenticated-orcid":false,"given":"Oscar","family":"Herrera-Restrepo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4731-6956","authenticated-orcid":false,"given":"Elizabeth","family":"Packnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0737-389X","authenticated-orcid":false,"given":"Megan","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3528-5507","authenticated-orcid":false,"given":"Elise","family":"Kuylen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5049-0111","authenticated-orcid":false,"given":"Tosin O.","family":"Olaiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0957-3118","authenticated-orcid":false,"given":"Thatiana","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8954-9064","authenticated-orcid":false,"given":"Lindsay","family":"Landgrave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9316-5810","authenticated-orcid":false,"given":"Ryan","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6879-9231","authenticated-orcid":false,"given":"Andrew G.","family":"Allmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"issue":"5","key":"676_CR1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.1979846","volume":"18","author":"J Presa","year":"2022","unstructured":"Presa J, Serra L, Weil-Olivier C, et al. Preventing invasive meningococcal disease in early infancy. Hum Vaccin Immunother. 2022;18(5):1979846.","journal-title":"Hum Vaccin Immunother"},{"key":"676_CR2","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268823000328","volume":"151","author":"C Pardo de Santayana","year":"2010","unstructured":"Pardo de Santayana C, Tin Tin Htar M, Findlow J, et al. Epidemiology of invasive meningococcal disease worldwide from 2010-2019: a literature review. Epidemiol Infect. 2023;151:e57.","journal-title":"Epidemiol Infect"},{"key":"676_CR3","unstructured":"CDC. Meningococcal disease surveillance and trends. 2025. Available at: https:\/\/www.cdc.gov\/meningococcal\/php\/surveillance\/index.html. Accessed 17 Feb 2026."},{"key":"676_CR4","unstructured":"Rubis A, Schillie S. Manual for the surveillance of vaccine-preventable diseases, Chapter 8: meningococcal disease. National Center for Immunization and Respiratory Diseases. Available at: https:\/\/www.cdc.gov\/surv-manual\/php\/table-of-contents\/chapter-8-meningococcal-disease.html. Accessed 3 July 2025."},{"issue":"12","key":"676_CR5","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1007\/s40121-024-01060-8","volume":"13","author":"O Herrera-Restrepo","year":"2024","unstructured":"Herrera-Restrepo O, Afroz N, Cabrera ES, et al. Life after invasive meningococcal disease: insights from survivors and their caregivers. Infect Dis Ther. 2024;13(12):2563\u201379.","journal-title":"Infect Dis Ther"},{"key":"676_CR6","unstructured":"CDC. Meningococcal disease symptoms and complications, 2026. Available at: https:\/\/www.cdc.gov\/meningococcal\/symptoms\/index.html. Accessed 28 July 2026."},{"issue":"1","key":"676_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-13342-2","volume":"22","author":"J Shen","year":"2022","unstructured":"Shen J, Begum N, Ruiz-Garcia Y, et al. Range of invasive meningococcal disease sequelae and health economic application \u2013 a systematic and clinical review. BMC Public Health. 2022;22(1):1078.","journal-title":"BMC Public Health"},{"issue":"1","key":"676_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/INF.0b013e3181ef25f7","volume":"30","author":"A Chandran","year":"2011","unstructured":"Chandran A, Herbert H, Misurski D, et al. Long-term sequelae of childhood bacterial meningitis: an underappreciated problem. Pediatr Infect Dis J. 2011;30(1):3\u20136.","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"676_CR9","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1086\/322587","volume":"33","author":"LJ Erickson","year":"2001","unstructured":"Erickson LJ, De Wals P, McMahon J, et al. Complications of meningococcal disease in college students. Clin Infect Dis. 2001;33(5):737\u20139.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"676_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112016","volume":"9","author":"H Petersen","year":"2014","unstructured":"Petersen H, Patel M, Ingason EF, et al. Long-term effects from bacterial meningitis in childhood and adolescence on postural control. PLoS One. 2014;9(11):e112016.","journal-title":"PLoS One"},{"issue":"9","key":"676_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6909a1","volume":"69","author":"SA Mbaeyi","year":"2020","unstructured":"Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2020;69(9):1\u201341.","journal-title":"MMWR Recomm Rep"},{"issue":"4","key":"676_CR12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jinf.2020.05.079","volume":"81","author":"SR Parikh","year":"2020","unstructured":"Parikh SR, Campbell H, Bettinger JA, et al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect. 2020;81(4):483\u201398.","journal-title":"J Infect"},{"issue":"4","key":"676_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0267786","volume":"17","author":"L Huang","year":"2022","unstructured":"Huang L, Fievez S, Goguillot M, et al. A database study of clinical and economic burden of invasive meningococcal disease in France. PLoS One. 2022;17(4):e0267786.","journal-title":"PLoS One"},{"issue":"1","key":"676_CR14","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2436039","volume":"20","author":"O Herrera-Restrepo","year":"2024","unstructured":"Herrera-Restrepo O, Kwiatkowska M, Huse S, et al. Retrospective analysis of health and economic burden among commercially-insured individuals diagnosed with invasive meningococcal disease in the United States. Hum Vaccin Immunother. 2024;20(1):2436039.","journal-title":"Hum Vaccin Immunother"},{"issue":"9","key":"676_CR15","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s00431-018-3192-0","volume":"177","author":"L Pickering","year":"2018","unstructured":"Pickering L, Jennum P, Ibsen R, et al. Long-term health and socioeconomic consequences of childhood and adolescent onset of meningococcal meningitis. Eur J Pediatr. 2018;177(9):1309\u201315.","journal-title":"Eur J Pediatr"},{"issue":"1","key":"676_CR16","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.2021764","volume":"18","author":"C Weil-Olivier","year":"2022","unstructured":"Weil-Olivier C, Taha MK, Bou\u00e9e S, et al. Care pathways in invasive meningococcal disease: a retrospective analysis of the French national public health insurance database. Hum Vaccin Immunother. 2022;18(1):2021764.","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"676_CR17","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1007\/s40121-024-01061-7","volume":"13","author":"O Herrera-Restrepo","year":"2024","unstructured":"Herrera-Restrepo O, Afroz N, Cabrera ES, et al. Initial experiences with invasive meningococcal disease: insights from survivors and their caregivers. Infect Dis Ther. 2024;13(12):2581\u201395.","journal-title":"Infect Dis Ther"},{"issue":"6","key":"676_CR18","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s40273-025-01477-0","volume":"43","author":"HA Shah","year":"2025","unstructured":"Shah HA, Jutlla G, Herrera-Restrepo O, et al. Market and non-market productivity losses associated with invasive meningococcal disease in the USA. Pharmacoeconomics. 2025;43(6):651\u201364.","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"676_CR19","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s40121-025-01181-8","volume":"14","author":"T Wolynn","year":"2025","unstructured":"Wolynn T, Grimes JB, Nerurkar S, et al. Long-term impacts of invasive meningococcal disease on survivors and their caregivers in the United States and Canada. Infect Dis Ther. 2025;14(8):1577\u201397.","journal-title":"Infect Dis Ther"},{"key":"676_CR20","unstructured":"CDC. Enhanced Meningococcal Disease Surveillance Report, 2023. 2025. Available from: https:\/\/www.cdc.gov\/meningococcal\/media\/pdfs\/2025\/04\/NCIRD-EMDS-Report-2023_508.pdf. Accessed 17 June 2025."},{"issue":"2","key":"676_CR21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.37737\/ace.22005","volume":"4","author":"M Iwagami","year":"2022","unstructured":"Iwagami M, Shinozaki T. Introduction to matching in case-control and cohort studies. Ann Clin Epidemiol. 2022;4(2):33\u201340.","journal-title":"Ann Clin Epidemiol"},{"issue":"11","key":"676_CR22","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1007\/s40121-024-01026-w","volume":"13","author":"GS Marshall","year":"2024","unstructured":"Marshall GS, McCormick ZL, Johns JS, et al. Understanding the sequelae of invasive meningococcal disease in the United States. Infect Dis Ther. 2024;13(11):2213\u201320.","journal-title":"Infect Dis Ther"},{"issue":"1","key":"676_CR23","first-page":"52","volume":"6","author":"LC Paramore","year":"2006","unstructured":"Paramore LC, Thomas SK, Knopf KB, et al. Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer. Clin Colorectal Cancer. 2006;6(1):52\u20138.","journal-title":"Clin Colorectal Cancer"},{"key":"676_CR24","unstructured":"US Department of Health and Human Services Office for Human Research Protections. 45 CFR 46 exemptions (2018 requirements) Subpart A. Basic HHS Policy for protection of human research subjects. 2023. Available from: https:\/\/www.ecfr.gov\/current\/title-45\/subtitle-A\/subchapter-A\/part-46#p-46.104(d). Accessed 6 June 2024."},{"issue":"4","key":"676_CR25","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40121-018-0213-2","volume":"7","author":"KJ Olbrich","year":"2018","unstructured":"Olbrich KJ, M\u00fcller D, Schumacher S, et al. Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers. Infect Dis Ther. 2018;7(4):421\u201338.","journal-title":"Infect Dis Ther"},{"issue":"3","key":"676_CR26","doi-asserted-by":"publisher","first-page":"655","DOI":"10.12669\/pjms.343.14373","volume":"34","author":"F Zeeshan","year":"2018","unstructured":"Zeeshan F, Bari A, Dugal MN, et al. Hearing impairment after acute bacterial meningitis in children. Pak J Med Sci. 2018;34(3):655\u20139.","journal-title":"Pak J Med Sci."},{"issue":"8","key":"676_CR27","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1093\/cid\/civ028","volume":"60","author":"M Sadarangani","year":"2015","unstructured":"Sadarangani M, Scheifele DW, Halperin SA, et al. Outcomes of invasive meningococcal disease in adults and children in Canada between 2002 and 2011: a prospective cohort study. Clin Infect Dis. 2015;60(8):e27-35.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"676_CR28","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1097\/INF.0000000000000282","volume":"33","author":"C Stein-Zamir","year":"2014","unstructured":"Stein-Zamir C, Shoob H, Sokolov I, et al. The clinical features and long-term sequelae of invasive meningococcal disease in children. Pediatr Infect Dis J. 2014;33(7):777\u20139.","journal-title":"Pediatr Infect Dis J"},{"issue":"37","key":"676_CR29","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1016\/j.vaccine.2014.05.069","volume":"32","author":"B Wang","year":"2014","unstructured":"Wang B, Haji Ali Afzali H, Marshall H. The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children. Vaccine. 2014;32(37):4791\u20138.","journal-title":"Vaccine"},{"issue":"3","key":"676_CR30","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1007\/s40121-021-00468-w","volume":"10","author":"C Weil-Olivier","year":"2021","unstructured":"Weil-Olivier C, Taha MK, Emery C, et al. Healthcare resource consumption and cost of invasive meningococcal disease in France: a study of the National Health Insurance Database. Infect Dis Ther. 2021;10(3):1607\u201323.","journal-title":"Infect Dis Ther"},{"key":"676_CR31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/PHMT.S182296","volume":"10","author":"KK McLaurin","year":"2019","unstructured":"McLaurin KK, Wade SW, Kong AM, et al. Characteristics and health care utilization of otherwise healthy commercially and Medicaid-insured preterm and full-term infants in the US. Pediatric Health Med Ther. 2019;10:21\u201331.","journal-title":"Pediatric Health Med Ther."},{"issue":"1","key":"676_CR32","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3390\/ijerph18010189","volume":"18","author":"C Carmassi","year":"2020","unstructured":"Carmassi C, Dell\u2019Oste V, Foghi C, et al. Post-traumatic stress reactions in caregivers of children and adolescents\/young adults with severe diseases: a systematic review of risk and protective factors. Int J Environ Res Public Health. 2020;18(1):189.","journal-title":"Int J Environ Res Public Health"},{"issue":"16","key":"676_CR33","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1001\/archinte.166.16.1749","volume":"166","author":"LJ Meltzer","year":"2006","unstructured":"Meltzer LJ, Mindell JA. Impact of a child\u2019s chronic illness on maternal sleep and daytime functioning. Arch Intern Med. 2006;166(16):1749\u201355.","journal-title":"Arch Intern Med"},{"issue":"5","key":"676_CR34","doi-asserted-by":"publisher","first-page":"642","DOI":"10.14744\/nci.2023.53533","volume":"10","author":"T Pasin","year":"2023","unstructured":"Pasin T, Karatekin BD, Pasin O. Chronic fatigue syndrome in caregivers of children with cerebral palsy and affecting factors. North Clin Istanb. 2023;10(5):642\u201350.","journal-title":"North Clin Istanb."},{"issue":"15","key":"676_CR35","doi-asserted-by":"publisher","first-page":"345","DOI":"10.15585\/mmwr.mm7315a4","volume":"73","author":"JP Collins","year":"2024","unstructured":"Collins JP, Crowe SJ, Ortega-Sanchez IR, et al. Use of the Pfizer pentavalent meningococcal vaccine among persons aged \u226510 years: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2024. MMWR Morb Mortal Wkly Rep. 2024;73(15):345\u201350.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"676_CR36","first-page":"464","volume":"8","author":"C Azzari","year":"2014","unstructured":"Azzari C, Moriondo M, Nieddu F, et al. Effectiveness and impact of the 4CMenB vaccine against group B meningococcal disease in two Italian regions using different vaccination schedules: a five-year retrospective observational study (2014-2018). Vaccines. 2020;8(3):469.","journal-title":"Vaccines"},{"issue":"5","key":"676_CR37","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2206433","volume":"388","author":"J Castilla","year":"2023","unstructured":"Castilla J, Garc\u00eda Cenoz M, Abad R, et al. Effectiveness of a meningococcal group B vaccine (4CMenB) in children. N Engl J Med. 2023;388(5):427\u201338.","journal-title":"N Engl J Med"},{"issue":"6","key":"676_CR38","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S2352-4642(18)30103-2","volume":"2","author":"P Bryan","year":"2018","unstructured":"Bryan P, Seabroke S, Wong J, et al. Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study. Lancet Child Adolesc Health. 2018;2(6):395\u2013403.","journal-title":"Lancet Child Adolesc Health"},{"issue":"4","key":"676_CR39","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s41669-024-00488-5","volume":"8","author":"G de Pouvourville","year":"2024","unstructured":"de Pouvourville G, Breau-Brunel M, Loncle-Provot V, et al. Public health impact and cost-effectiveness analysis of 4-component meningococcal serotype B vaccination for infants in France. PharmacoEcon Open. 2024;8(4):539\u201357.","journal-title":"PharmacoEcon Open"},{"issue":"1","key":"676_CR40","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40121-021-00573-w","volume":"11","author":"S Scholz","year":"2022","unstructured":"Scholz S, Schwarz M, Beck E, et al. Public health impact and cost-effectiveness analysis of routine infant 4CMenB vaccination in Germany to prevent serogroup B invasive meningococcal disease. Infect Dis Ther. 2022;11(1):367\u201387.","journal-title":"Infect Dis Ther"},{"key":"676_CR41","unstructured":"Conmy AB, PC, De Lew N, Sommers BD. Children\u2019s health coverage trends: gains in 2020\u20132022 reverse previous coverage losses. (Issue Brief No. HP-2023-07). Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services. 2023. Available at: https:\/\/aspe.hhs.gov\/sites\/default\/files\/documents\/77d7cc41648a371e0b5128f0dec2470e\/aspe-childrens-health-coverage.pdf. Accessed 3 July 2025."}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-026-00676-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-026-00676-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-026-00676-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T08:33:25Z","timestamp":1789979605000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-026-00676-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":41,"alternative-id":["676"],"URL":"https:\/\/doi.org\/10.1007\/s41669-026-00676-5","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Oscar Herrera-Restrepo, Elise Kuylen, Tosin O. Olaiya, Thatiana Pinto, Lindsay C. Landgrave, and Andrew G. Allmon are employees of and hold financial equities in GSK. Elizabeth Packnett, Megan K. Richards, and Ryan Ross are employees of Merative, which was paid by GSK to conduct this study.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was considered non-human subjects research and did not require informed consent, ethics committee, or Institutional Review Board review.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":3,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Substantial contributions to study conception and design: OHR, EP, MR, EK, TO, LL, AGA; substantial contributions to analysis and interpretation of the data: OHR, EP, MR, EK, TO, TP, LL, RR, AGA; drafting the article or revising it critically for important intellectual content: OHR, EP, MR, EK, TO, TP, LL, RR, AGA; final approval of the version of the article to be published: OHR, EP, MR, EK, TO, TP, LL, RR, AGA.","order":7,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}